RxDoctor Payments Data

Richard Bernstein, MD

Vascular Neurology · Chicago, ILNPI 1164498614

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2019 at $50,391 and has fallen 64.3% since, to $18,000 in 2025. Among vascular neurology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$113,897in general payments, 2019–2025

Across 97 payments — averaging $1174.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Abbott$20K
  • AbbVie$18K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Boehringer Ingelheim International GmbH$13K
  • Amgen$9K
  • plus $15K from 4 others
$11,468in research payments, 2019–2025

Across 4 payments — averaging $2867.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$10K
  • Medtronic$1K

What the payments were for

  • Consulting fees$51,48045%
  • Speaking & faculty fees$35,47531%
  • Travel & lodging$25,33822%
  • Food & beverage$1,6041%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$113,897 in reported general payments places this provider in the 90th percentile of 32 vascular neurology providers in Illinois.

See all vascular neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$108,484
Medicare patients
503
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$138,700
XareltoRivaroxaban38$26,470
BrilintaTicagrelor13$5,941
Aspirin-Dipyridamole ErAspirin/Dipyridamole33$5,341
ClopidogrelClopidogrel Bisulfate105$1,712
Atorvastatin Calcium69$1,007
Levetiracetam41$938
Pregabalin39$612
Gabapentin32$371
Nortriptyline Hcl21$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$3,964$5,94113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 32 vascular neurology providers in Illinois.

Other vascular neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →